Overview

Comparison of Two Dosing Regimens of Intravenous Ketorolac for Post-Cesarean Pain Control

Status:
NOT_YET_RECRUITING
Trial end date:
2026-03-01
Target enrollment:
Participant gender:
Summary
Ketorolac, an intravenous NSAID widely used in perioperative pain management, has been shown to reduce pain scores and opioid requirements following cesarean delivery. However, its optimal dosing regimen remains uncertain, with previous studies using doses ranging from 15 mg to 60 mg. A retrospective analysis found no significant difference between 15 mg and 30 mg doses when combined with neuraxial opioids, possibly due to overlapping multimodal analgesia components. To date, no study has directly compared the analgesic efficacy of two intravenous ketorolac dosing regimens as part of a multimodal analgesic protocol that includes local wound infiltration for postoperative pain management after elective cesarean delivery.
Phase:
NA
Details
Lead Sponsor:
Cairo University
Treatments:
Ketorolac